{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 33,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide highlights a 'vaccine effect' in 13/15 animals and mentions IP protection for these combinations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/21",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Combining I/O and DDRi Therapeutics with TATs to potentially improve efficacy and increase addressable patient populations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a5cfa88-b2e9-42ce-aa9b-68694c0bf207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "chart",
      "text": "FPI-1434 + Olaparib PARP Insensitive Tumor",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21fbb188-b9bf-4b23-8948-045d2eb190e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Fusion is Pioneering TAT + I/O Research: Immune Competent Mouse CT-26 Colorectal Tumor -> Treat (TAT + CPIs) -> Try to re-grow the tumor",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b931115-4efd-46b4-bea7-a3bbf4bb345c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Results: 13 of 15 animals did not grow a second tumor \"Vaccine effect\" indicates synergistic effects of combining with I/O and supports opportunity expand market",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c86cf19-1c32-41d4-86f9-ad715e5e7848",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 1,
        "x": 0,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Fusion has issued IP on combination of 225Ac and I/O drugs and patent pending on combination of 225Ac and DDRi",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cdeac82-3e81-4c19-bcb2-145899b5bec0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Fusion's Strategy Around Combination Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab68d951-e91f-4e77-929c-de9620406451",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "53ba8f56-a7d6-4208-afce-536f5d59548f",
      "evidence": "FPI-1434 + Olaparib PARP Insensitive Tumor",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}